24303-64-8

Basic information

• Product Name: 4-Methoxy-but-2-ynoic acid
• Synonyms: 4-Methoxy-but-2-ynoic acid;4-methoxy-2-Butynoic acid
• CAS NO: 24303-64-8
• Molecular Formula: C₅H₆O₃
• Molecular Weight: 114.09934
• Mol File: 24303-64-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 114-118 °C(Press: 3 Torr)
• Appearance: /
• Density: 1.196±0.06 g/cm3(Predicted)
• PKA: 2.10±0.10(Predicted)
• CAS DataBase Reference: 4-Methoxy-but-2-ynoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-but-2-ynoic acid(24303-64-8)
• EPA Substance Registry System: 4-Methoxy-but-2-ynoic acid(24303-64-8)

Safety Data

• Hazardous Substances Data: 24303-64-8(Hazardous Substances Data)

Usage

Description

4-Methoxy-but-2-ynoic acid is a chemical compound with the molecular formula C6H8O3. It is a derivative of butynoic acid, containing a methoxy group (-OCH3) attached to the carbon atom in the fourth position of the butynoic acid chain. As a carboxylic acid, it contains a carboxyl group (-COOH) and exhibits acidic properties. 4-Methoxy-but-2-ynoic acid serves as a versatile building block in organic synthesis and holds potential for applications in various fields, including pharmaceuticals, agrochemicals, and medicinal chemistry, due to its unique structural properties and possible biological activities.

Uses

Used in Organic Synthesis:
4-Methoxy-but-2-ynoic acid is used as a building block in organic synthesis for the creation of a wide range of chemical products. Its unique structure allows for the development of novel compounds with specific properties, making it valuable in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-Methoxy-but-2-ynoic acid is utilized as a key intermediate in the synthesis of various drugs. Its acidic nature and structural features enable the production of molecules with specific therapeutic effects, contributing to the development of new medications.
Used in Agrochemical Development:
4-Methoxy-but-2-ynoic acid is employed in the agrochemical sector as a precursor for the synthesis of pesticides, herbicides, and other crop protection agents. Its chemical properties allow for the creation of effective and targeted agrochemicals that can improve agricultural productivity and crop protection.
Used in Medicinal Chemistry Research:
Due to its potential biological activities and structural properties, 4-Methoxy-but-2-ynoic acid is used in medicinal chemistry research to explore its therapeutic potential. It may serve as a starting point for the development of new drugs or as a tool to understand the mechanisms of action of existing medications.

Upstream product

• 676-58-4 methylmagnesium chloride 
• 627-41-8 propargyl alcohol methyl ether 
• 124-38-9 carbon dioxide 

Downstream Products

• 214485-51-5 N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinolinyl}-4-methoxy-2-butynamide 
• 1431958-84-7 C₂₁H₂₁N₅O₂S 

Relevant articles and documents

Carboxylation of Terminal Alkynes with Carbon Dioxide Catalyzed by an In Situ Ag2O/N-Heterocyclic Carbene Precursor System

A carboxylation of terminal alkynes with carbon dioxide (CO2) at ambient conditions was developed in situ using a series of N-heterocyclic carbene (NHC) precursors and Ag2O. The unique structure of NHCs largely increases the solubility of active Ag species and meanwhile activates CO2 by forming the NHC–CO2 adduct. This novel catalytic system demonstrated quite low Ag loading, very high activities, wide substrate generality and excellent tolerance for a variety of functionalities. In addition, avoiding cumbersome synthesis procedures, processing, and reserving of the photosensitive Ag complex, this system could be stored and operated as straightforward as the inorganic Ag salt catalysts.

OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4 and R5 and defined herein.

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.